{"entity":{"id":"nct04810078","kind":"trial","name":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance","aka":["CheckMate-67T"],"tldr":"A phase 3 trial of Nivolumab in renal cell carcinoma, run by Bristol-Myers Squibb, active and no longer recruiting.","summary":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread is a phase 3 interventional study registered as NCT04810078 by Bristol-Myers Squibb, with 681 participants enrolled, started 2021-05-21 and due to reach its primary completion in 2025-07-29. Interventions recorded: Nivolumab and rHuPH20, Nivolumab. Conditions listed: Clear Cell Renal Cell Carcinoma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04810078","url":"https://clinicaltrials.gov/study/NCT04810078"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc","clear-cell-rcc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04810078","phase":"3","setting":"A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy","sponsor":"Bristol-Myers Squibb","started":"2021-05-21","startedType":"actual","yearReported":2026,"enrolled":681,"enrolledBasis":"registry","outcomes":[{"endpoint":"Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale","primary":true,"unit":"μg/ml","arms":[{"name":"Nivolumab SC","n":242,"value":77.373,"note":"90% CI 74.555 to 80.297; Figures from the ClinicalTrials.gov results section (first posted 2026-09-22), not from a publication"},{"name":"Nivolumab IV","n":245,"value":36.875,"note":"90% CI 35.565 to 38.235"},{"name":"Nivo SC Process C","n":93,"value":75.504,"note":"90% CI 70.941 to 80.361"},{"name":"Nivo SC Process D","n":93,"value":75.596,"note":"90% CI 71.019 to 80.468"}],"source":"https://clinicaltrials.gov/study/NCT04810078?tab=results"},{"endpoint":"Objective Response Rate (ORR) Per BICR","unit":"%","arms":[{"name":"Nivolumab SC","n":248,"value":24.2,"note":"95% CI 19.0 to 30.0; Figures from the ClinicalTrials.gov results section (first posted 2026-09-22), not from a publication"},{"name":"Nivolumab IV","n":247,"value":18.2,"note":"95% CI 13.6 to 23.6"}],"source":"https://clinicaltrials.gov/study/NCT04810078?tab=results"}]},"route":"/trials/nct04810078/","neighbours":{"cancer":[{"id":"clear-cell-rcc","kind":"cancer","name":"Clear cell renal cell carcinoma","route":"/cancers/clear-cell-rcc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}